Avanir pays OptiNose $20m for NDA-ready migraine drug-device
This article was originally published in Scrip
Executive Summary
Avanir Pharmaceuticals will pay $20 million up front to license the North American rights for an inhaled migraine drug from OptiNose, but the product candidate has not been tested against generic intranasal therapies to prove that its rapid onset of pain relief is a truly differentiating factor.
You may also be interested in...
Finance Watch: $50m Doubles Magenta's Funding To Improve Stem Cell Transplants
In VC deals, Magenta raised $50m, licensed a Novartis asset and engaged an important partner. Seven public companies revealed financial transactions totaling $947.4m, including Achaogen's $20.5m from the Gates Foundation. Also, OncoMed, Regulus and Depomed provided restructuring updates.
Amgen Hands Omecamtiv Back To Cytokinetics
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Finance Watch: Olema IPO Raises $209m To Advance OPI-1250 For Breast Cancer
Olema launched this year’s 76th US biopharma IPO. Also, investments in regenerative medicines reached a new high, Qiming closed a $1.2bn China-focused VC fund, D3 Bio led recent venture deals with a $200m round, and Bausch sold $2bn worth of notes to pay down near-term debts.
Need a specific report? 1000+ reports available
Buy Reports